Top Banner
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Hypothalamic and Pituitary Agents Chapter 35
29

Ppt chapter 35-1

Nov 28, 2014

Download

Documents

stanbridge

 
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hypothalamic and Pituitary Agents

Hypothalamic and Pituitary Agents

Chapter 35

Page 2: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Endocrine SystemEndocrine System

• Main function is to maintain homeostasis

• Too much or too little glandular activity

– Disrupts homeostasis

– Leads to various disorders

– Interferes with the normal functioning of other endocrine glands

Page 3: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hypothalamic Releasing Factors With Diagnostic Functions

Hypothalamic Releasing Factors With Diagnostic Functions

• CRH

– Stimulates release of ACTH from anterior pituitary

– Used to diagnose Cushing’s disease

• Gonadorelin (Factrel)

– GnRH analog

– Checks for anterior pituitary response and gonadotropin deficiency

Page 4: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hypothalamic Releasing Factors With Diagnostic Functions (cont.)

Hypothalamic Releasing Factors With Diagnostic Functions (cont.)

• TRH (Protirelin)

– Stimulates the pituitary to produce thyrotropin, which stimulates the thyroid to produce thyroid hormones

• GHRH (Sermorelin)

– Stimulates the production of growth hormone (GH) by the anterior pituitary

Page 5: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions

Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions

• Goserelin (Zoladex)

– Analog of GnRH; inhibits pituitary gonadotropin secretion with a resultant drop in the production of the sex hormones

• Histrelin (Supprelin), Ganirelix (Antagon), and Abarelix (Plenaxis)

– GnRH agonists; inhibits gonadotropin secretion and decrease the levels of steroid sex hormones

Page 6: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions (cont.)Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions (cont.)

• Leuprolide (Lupron)

– Occupies pituitary GnRH receptor sites so that they no longer respond to GnRH

• Nafarelin (Synarel)

– A potent agonist of GnRH; decreases production of gonadal hormones by repeated stimulation of receptor sites

Page 7: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Site of Action of Hypothalamic and Pituitary Agents

Site of Action of Hypothalamic and Pituitary Agents

Page 8: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anterior Pituitary Hormones and Their Indications

Anterior Pituitary Hormones and Their Indications

• Chorionic Gonadotropin (Chorex): Hypogonadism, ovulation, prepubertal cryptorchidism

• Corticotropin (Acthar), or ACTH: Test adrenal function and responsiveness

• Cosyntropin (Cortrosyn): Diagnose adrenal dysfunction

• Menotropins (Pergonal): Fertility drug

• Somatropin (Nutropin, etc.): Growth failure, Turner’s syndrome, AIDS, growth hormone deficiency

Page 9: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anterior Pituitary Hormones and Their Indications (cont.)

Anterior Pituitary Hormones and Their Indications (cont.)

• Somatropin rDNA origin (Zorbtive): Short bowel syndrome

• Thyrotropin (Thytropar): Diagnostic agent to evaluate thyroid function

• Somatrem (Protropin): Treat children with growth failure

Page 10: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anterior Pituitary HormonesAnterior Pituitary Hormones

• Actions

– Somatropin is a hormone of recombinant DNA origin that is equivalent to human growth hormone

• Indications

– Used in patients experiencing growth

• Pharmacokinetics

– Injected and reaches peak in 7 hours

– Widely distributed in the body

– Excreted through urine and feces

Page 11: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anterior Pituitary Hormones (cont.) Anterior Pituitary Hormones (cont.)

• Contraindications

– Known allergy

– Allergy to ingredients in the drug

– Presence of closed epiphyses

– Underlying cranial lesions

Page 12: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Anterior Pituitary Hormones (cont.)Anterior Pituitary Hormones (cont.)

• Adverse Reactions

– Inflammation

– Swelling and joint pain

– Hypothyroidism and insulin resistance

Page 13: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Please answer the following statement as true or false.

Somatropin is a hormone of recombinant DNA origin that is equivalent to human growth hormone.

Page 14: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

True

Rationale: Somatropin replaces human growth hormone; stimulates skeletal growth, growth of internal organs, and

protein synthesis.

Page 15: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Growth Hormone AntagonistsGrowth Hormone Antagonists

• Actions

– Is an inhibitory factor released from the hypothalamus

– Not used to decrease GH

– Has multiple effects on many of the secretory systems

• Indications

– Treatment of acromegaly

• Pharmacokinetics

– Varies depending on the drug

Page 16: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Growth Hormone Antagonists (cont.)Growth Hormone Antagonists (cont.)

• Contraindications

– Known allergy

• Caution

– Pregnancy or lactation

– Presence of any other endocrine disorder

• Adverse Reactions

– Varies with each medication

Page 17: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Posterior Pituitary HormonesPosterior Pituitary Hormones

• Indications

– Treatment of neurogenic diabetes insipidus

– Desmopressin is also indicated for the treatment of hemophilia A and von Willebrand’s disease

– Nocturnal enuresis

• Pharmacokinetics

– Rapidly absorbed and metabolized

– Excreted in the liver and kidneys

– Not used during pregnancy due to the risk of uterine contractions

Page 18: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Posterior Pituitary Hormones (cont.)Posterior Pituitary Hormones (cont.)

• Contraindications

– Known allergy

– Severe renal dysfunction

• Caution

– Known vascular disease

– Epilepsy

– Asthma

– Pregnancy

– Lactation

Page 19: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Posterior Pituitary Hormones (cont.)Posterior Pituitary Hormones (cont.)

• Adverse Reactions

– Water intoxication

• Related to the shift in water retention

– Stimulation of GI tract

– Local nasal irritation

– Hypersensitivity

Page 20: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Use of Hypothalamic and Pituitary Agents Across the Lifespan

Use of Hypothalamic and Pituitary Agents Across the Lifespan

Page 21: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Hypothalamic Releasing Factors

Prototype Hypothalamic Releasing Factors

Page 22: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Hypothalamic Releasing Factors (Contiuned)

Prototype Hypothalamic Releasing Factors (Contiuned)

Page 23: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Anterior Pituitary Hormones – Growth Hormone, Agonist

Prototype Anterior Pituitary Hormones – Growth Hormone, Agonist

Page 24: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Anterior Pituitary Hormones – Growth Hormone, Antagonist

Prototype Anterior Pituitary Hormones – Growth Hormone, Antagonist

Page 25: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Prototype Anterior Pituitary Hormones – Growth Hormone, Antagonist (Continued)Prototype Anterior Pituitary Hormones –

Growth Hormone, Antagonist (Continued)

Page 26: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Anterior Pituitary Hormones – Growth Hormone

Nursing Considerations for Anterior Pituitary Hormones – Growth Hormone

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 27: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing Considerations for Posterior Pituitary Hormones

Nursing Considerations for Posterior Pituitary Hormones

• Assessment: History and Physical Exam

• Nursing Diagnosis

• Implementation

• Evaluation

Page 28: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

The nurse is caring for a 10-year-old boy with growth hormone deficiency. The child asks the nurse how long he will be able to take his medicine. Which of the following is best response?

A. Until you decide to stop

B. Until you are 13

C. Until your epiphyseal plates close

D. Until you get as tall as you want to be

Page 29: Ppt chapter 35-1

Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

C. Until your epiphyseal plates close

Rationale: In normal growth and development growth ceases when the epiphyseal plates fuse to the ends of the long bones.